{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "BRBR",
  "name": "BellRing Brands, Inc.",
  "url": "https://frontierpicks.com/dossiers/BRBR/",
  "json_url": "https://frontierpicks.com/dossiers/BRBR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "The $11–12 post-print shelf broke on no news: $11.56 on 2026-08-07 to $10.75 on 2026-08-14, RSI 27.9, -74.8% off the $42.68 high. A third FY26 EBITDA cut ($275–295M from $315–335M) killed the margin narrative; the repair — a double-digit Premier shake price increase effective Q1 FY2027 — is untestable until the ~mid-November Q4 print. No dated catalyst inside 30 days.",
  "invalidation_trigger": "A weekly close below $10.40 abandons the last shelf to survive the 2026-08-04 print and re-exposes the May 2026 low area; a fourth FY-EBITDA reduction at the ~mid-November Q4 report — reported FY26 adjusted EBITDA under $275M or an initial FY2027 guide beneath that range — would confirm the reset is open-ended.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "fintech-consumer-credit",
    "consumer-discretionary-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Fiscal year ends September 30; Q4 and full-year results have historically landed mid-November (FY2025 reported 2025-11-18).",
    "Single-brand concentration: Premier Protein RTD dominates the mix, so club and retail shelf resets are outsized events with no diversification cushion.",
    "Stockholders' deficit of $(467.2)M at 2026-06-30 is structural to the post-spin capital structure; negative book equity here is not by itself a distress signal.",
    "Michael Axelrod became President and CEO effective 2026-07-29; Q4 FY2026 is his first full quarter and the first outlook issued under him.",
    "The FY2026 adjusted-EBITDA outlook was reduced at consecutive prints (2026-05-05 and 2026-08-04); any single guide should be read as provisional.",
    "The announced Q1 FY2027 price increase takes effect in a quarter that does not report until early February 2027."
  ],
  "body_markdown": "\n_Reference close: $10.75 (2026-08-14). All levels below are market levels._\n\n## BRBR — BellRing Brands, Inc.\n\n## Current Thesis\nThe $11–12 shelf that this coverage described on 2026-08-08 did not hold. Price went from $11.56 on 2026-08-07 to $10.75 on 2026-08-14, RSI(14) at 27.9, now -74.8% below the $42.68 52-week high. Nothing new was filed or reported in that window — StockTitan's BRBR feed carries no company item after the 2026-08-04 release, and no Form 4 activity surfaced through 2026-08-16. The move is therefore a re-rating on the already-known facts of the print rather than a reaction to fresh news: FY2026 adjusted EBITDA cut to $275–295M from $315–335M, the third reduction to that line this fiscal year, against a raised net-sales guide of $2.335–2.375B.\n\nWhat remains for an investor is a narrower proposition than the one on offer in July. Demand is intact (Q3 net sales $570.4M, +4.0% YoY, ahead of the $547.762M consensus). The profit damage is itemized: a $10.0M Q3 shake-bottle inventory charge, $21.3M across nine months, $28M of stated full-year impact including roughly $7M of Q4 trade spend. And management named its repair lever on the 2026-08-04 call — a double-digit price increase on Premier shakes plus additional powder pricing, effective in Q1 fiscal 2027, which begins 2026-10-01. That lever is unobservable in reported numbers until the ~mid-November Q4 report and unobservable in results until the Q1 FY2027 print in early February. The interval between now and then contains no dated company event.\n\n## Bull Case\n- Q3 FY2026 net sales $570.4M, +4.0% YoY (volume +1.7%, price/mix +2.5%), above the $547.762M consensus; FY2026 net-sales guidance was raised to $2.335–2.375B from $2.325–2.365B on 2026-08-04. Company-level price/mix turned positive after a deeply negative Q2 mix quarter.\n- Management committed on 2026-08-04 to a double-digit price increase on Premier shakes and additional pricing on powders effective Q1 FY2027 (quarter begins 2026-10-01). This is a direct, dated attack on the 13.7% Q3 margin rather than a cost-savings promise.\n- Dymatize net sales +26.7% YoY in Q3 FY2026 on volume +6.0% and price/mix +20.7% — evidence that the portfolio can take price where the brand supports it.\n- The margin hit is sized and dated: $10.0M Q3 charge (180bp of margin), $21.3M over nine months, $28M stated full-year impact. Management attributes the bottle write-down to cannibalization by the e-commerce tetra format, a mix shift inside its own demand.\n- Seven sell-side targets set between 2026-07-09 and 2026-08-05 — Stephens $20, JP Morgan $17, DA Davidson $15, Stifel $15, Barclays $14, UBS $13.5, TD Cowen $12 — all sit above the 2026-08-14 close of $10.75. Two of those (DA Davidson, TD Cowen) were raised the day after the guide cut.\n- $506.9M of repurchase authorization remained at 2026-06-30.\n- The three-month return through 2026-08-14 is +10.9%, so the May 2026 trough area near $9.20 (Investing.com 52-week-low report; a 2026-05-15 analyst note referenced a $9.15 share price) has not been retested despite the August guide cut.\n\n## Bear Case\n- Two consecutive misses against management's own margin guide: ~13% guided into Q2 versus a 9% result; ~16% guided into Q3 versus 13.7%. The FY26 adjusted-EBITDA range was cut roughly 13% in a single quarter on 2026-08-04.\n- The core brand is close to flat. Premier Protein net sales +0.7% YoY in Q3 (volume +1.5%, price/mix -0.8%); RTD shakes +1.2% (volume +3.1%, price/mix -1.9%). Taking a double-digit price increase into a line whose price/mix is already negative is an untested elasticity bet.\n- Working capital deteriorated: inventories $480.6M at 2026-06-30 versus $330.4M at 2025-09-30, against nine-month net sales of $1,706.4M (+2.3%). Nine-month operating cash flow was $65.0M.\n- Long-term debt $1,135.3M against $50.4M cash and a lowered $275–295M FY26 EBITDA guide; stockholders' deficit $(467.2)M at 2026-06-30.\n- The buyback ran at an average $27.41 per share across 4.9 million shares for $133.1M in the nine months to 2026-06-30 — capital deployed far above the current market level, which is a fact about timing, not about the remaining $506.9M authorization.\n- Michael Axelrod became President and CEO effective 2026-07-29. A new CEO issuing his first full-year outlook in mid-November has an incentive structure that historically favours a conservative reset.\n\n## Setup & Price Structure\nThe narrative is **dead**. The narrative an investor bought — a single-brand protein compounder with mid-teens margins — failed on measurable grounds, and the structure went with it. Dating it: three reductions to the FY26 adjusted-EBITDA line this fiscal year, the last on 2026-08-04; drawdown of -74.8% from the $42.68 52-week high as of 2026-08-14; and the loss of the $11–12 post-print shelf between 2026-08-07 ($11.56) and 2026-08-14 ($10.75) on no new information. What trades now is a margin-repair and valuation question, not the growth story.\n\nObservables on positioning, without a verdict attached to each:\n- The distance between price and published targets widened as price fell. Seven targets $12–$20 (2026-07-09 to 2026-08-05) all sit above $10.75; none has been cut since the 2026-08-04 guide reduction, so published estimates have not yet been marked to the new EBITDA range.\n- RSI(14) of 27.9 at the 2026-08-14 close is in oversold territory, reached without a headline in the window.\n- No earnings date inside 30 days. The next company-controlled event is fiscal year end 2026-09-30; the next disclosure is the ~mid-November Q4 report. That is roughly three months with no scheduled catalyst.\n- No insider Form 4 transactions and no issuance appeared on the tape between the 2026-08-04 print and 2026-08-16.\n- The company itself was the marginal buyer at an average $27.41 through 2026-06-30; whether it remained one below $11 is not disclosed until the 10-K.\n\nStructurally, the reference points are the broken $11–12 shelf above and the May 2026 low area near $9.20 below. The stock is between them with no dated event to resolve which side it works toward.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-30** — Fiscal 2026 year end. Fixes the balance-sheet date at which the $480.6M inventory build and the stated $28M of FY26 inventory-related actions are struck, and sets the base FY2027 laps. Outside the 30-day window by roughly two weeks.\n- **2026-10-01 (est.)** — Q1 FY2027 begins; the double-digit Premier shake price increase and powder pricing take effect. First scanner-data read on elasticity follows in the weeks after.\n- **~2026-11-17 (est.)** — Q4 and full-year FY2026 results plus initial FY2027 outlook. Date unconfirmed; FY2025 Q4 was reported 2025-11-18.\n\n## Elapsed catalysts\n\n- **No dated company catalyst falls inside the 30 days from 2026-08-16.** The gap is real and is part of the setup. *(passed 10d ago)*\n\n## What Would Change Our Mind\nThe structure already gave up the shelf that held the print, so the first thing that would change the read is the opposite: reclaiming and holding $12 on a weekly basis would say the 2026-08-14 low was liquidation into an oversold tape rather than the start of a leg toward the May area.\n\nDownward, the gradeable condition is **a weekly close below $10.40**, which abandons the last shelf to survive the 2026-08-04 print and re-exposes the May 2026 low area near $9.20. Secondary conditions that would confirm the reset is open-ended rather than finite: FY2026 adjusted EBITDA reported below the $275M low end at the ~mid-November Q4 print; an initial FY2027 adjusted-EBITDA guide set beneath the $275–295M FY26 range; or the Q1 FY2027 pricing action being deferred, reduced or walked back on that call.\n\nWhat would rebuild the case: inventories down materially from $480.6M at the fiscal-year-end balance sheet, no new excess-inventory charge beyond the sized $28M, and Premier Protein price/mix turning positive as the increase lands.\n\n## Correlation Notes\n- Single-brand concentration means BRBR does not track the packaged-food complex closely on fundamentals. Club and mass shelf-reset decisions move the numbers more than aggregate consumer spending does; Premier Protein RTD dominates the mix with no diversification cushion.\n- The high-protein consumption theme (GLP-1-adjacent demand) is intact in this company's own data — Q3 volume +1.7%, RTD volume +3.1% — so the stock's drawdown is being driven by unit economics rather than category demand. That decoupling is inference from the segment disclosures, not a measured factor loading.\n- Dairy-protein and freight input costs, plus the trade-spend needed to clear bottled-shake inventory, are the operating variables between here and the FY2027 pricing action; none of them publishes on a schedule the equity can trade against before mid-November.\n- Sell-side dispersion is wide for a $2.3B-revenue consumer name — $12 to $20 among seven firms in a four-week span — which is itself a statement about how little agreement exists on normalized margin.",
  "first_seen": "2026-06-26",
  "last_analyzed": "2026-08-16T17:23:58+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}